Skip to main content
Top
Published in: BMC Infectious Diseases 1/2016

Open Access 01-12-2016 | Research article

Factors associated with 10 years of continuous viral load suppression on HAART

Authors: Kathryn J. Bello, Octavio Mesner, Thomas A. O’Bryan, Seung Hyun Won, Tahaniyat Lalani, Anuradha Ganesan, Brian K. Agan, Jason F. Okulicz

Published in: BMC Infectious Diseases | Issue 1/2016

Login to get access

Abstract

Background

The principal goal of HAART is sustained viral load (VL) suppression resulting in immune reconstitution and improved HIV outcomes. We studied the factors associated with 10 years of continuous VL suppression on HAART in the US Military HIV Natural History Study.

Methods

Participants with continuous VL suppression (CS, n = 149) were compared to those who did not have continuous viral load suppression (NCS, n = 127) for ≥10 years on HAART. Factors associated with >10 years of VL suppression were evaluated by multivariate logistic regression. Additionally, association between CS and CD4 reconstitution was analyzed with a mixed effects model.

Results

Compared to NCS participants, a lower proportion of CS participants started HAART in the early HAART era (66 vs 90 %, for years 1996–1999; p < 0.001) and had less antiretroviral use prior to HAART (37 vs 83 %; p < 0.001). At initial HAART, the median CD4 cell count was higher and VL was lower for CS compared to NCS participants (375 cells/uL [256, 499] vs 261 cells/uL [146, 400]; p < 0.001 and 4.4 log10 copies/mL [3.5, 4.9] vs 4.5 log10 copies/mL [3.8, 5.0]; p = 0.048, respectively). New AIDS events were lower during HAART (5 vs 13 %; p = 0.032) and post-HAART CD4 trajectories were greater for the CS compared to NCS group. Factors negatively associated with ≥10 years of VL suppression included log10 VL at first HAART (OR 0.61, 95 % CI 0.4, 0.92; p = 0.020) and antiretroviral use prior to HAART (OR 0.16, 95 % CI 0.06, 0.38; p < .001).

Conclusions

Sustained VL suppression is a key to long-term health in HIV-infected patients, as demonstrated by the lower proportion of AIDS events observed 10 years after HAART initiation. The current use of more potent and well-tolerated regimens may mitigate the negative factors of pre-HAART VL and prior ARV use encountered by treatment initiated in the early HAART era.
Literature
1.
go back to reference Al-Harthia L, Siegela J, Spritzlerb J, Pottagec J, Agnolic M, Landaya A. Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease. AIDS. 2000;14:761–70.CrossRef Al-Harthia L, Siegela J, Spritzlerb J, Pottagec J, Agnolic M, Landaya A. Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease. AIDS. 2000;14:761–70.CrossRef
2.
go back to reference Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Page-Shafer K, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis. 2008;197:126–33.CrossRefPubMedPubMedCentral Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Page-Shafer K, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis. 2008;197:126–33.CrossRefPubMedPubMedCentral
3.
go back to reference Landrum ML, Huppler Hullsiek K, Ganesan A, Weintrob AC, Crum-Cianflone NF, Barthel RV, et al. Hepatitis B vaccine responses in a large U.S. Military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4 count. Vaccine. 2009;27:4731–8.CrossRefPubMedPubMedCentral Landrum ML, Huppler Hullsiek K, Ganesan A, Weintrob AC, Crum-Cianflone NF, Barthel RV, et al. Hepatitis B vaccine responses in a large U.S. Military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4 count. Vaccine. 2009;27:4731–8.CrossRefPubMedPubMedCentral
4.
go back to reference Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, Lindegren ML, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the united states in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;30:S5–S14.CrossRefPubMed Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, Lindegren ML, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the united states in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;30:S5–S14.CrossRefPubMed
5.
go back to reference Freiberg MS, Chang CH, Kuller LH, Skanderson M, Lowy E, Kraemer KL, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173:614–22.CrossRefPubMedPubMedCentral Freiberg MS, Chang CH, Kuller LH, Skanderson M, Lowy E, Kraemer KL, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173:614–22.CrossRefPubMedPubMedCentral
6.
go back to reference The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283–96.CrossRef The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283–96.CrossRef
7.
go back to reference Nakagawa F, Lodwick RK, Smith CJ, Smith R, Cambiano V, Lundgren JD, et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS. 2012;26:335–43.CrossRefPubMed Nakagawa F, Lodwick RK, Smith CJ, Smith R, Cambiano V, Lundgren JD, et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS. 2012;26:335–43.CrossRefPubMed
8.
go back to reference Richman DD, Morton SC, Wrin T, Hellmann N, Berry S, Shapiro MF, et al. The prevalence of antiretroviral drug resistance in the united states. AIDS. 2004;18:1393–401.CrossRefPubMed Richman DD, Morton SC, Wrin T, Hellmann N, Berry S, Shapiro MF, et al. The prevalence of antiretroviral drug resistance in the united states. AIDS. 2004;18:1393–401.CrossRefPubMed
9.
go back to reference Gray KM, Cohen SM, Hu X, Li J, Mermin J, Hall HI. Jurisdiction level differences in HIV diagnosis, retention in care, and viral suppression in the united states. JAIDS. 2014;65:129–32.PubMed Gray KM, Cohen SM, Hu X, Li J, Mermin J, Hall HI. Jurisdiction level differences in HIV diagnosis, retention in care, and viral suppression in the united states. JAIDS. 2014;65:129–32.PubMed
10.
go back to reference Marconi VC, Grandits GA, Weintrob AC, Chun H, Landrum ML, Ganesan A, et al. Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the US military HIV natural history study. AIDS Res Ther. 2010;7:14.CrossRefPubMedPubMedCentral Marconi VC, Grandits GA, Weintrob AC, Chun H, Landrum ML, Ganesan A, et al. Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the US military HIV natural history study. AIDS Res Ther. 2010;7:14.CrossRefPubMedPubMedCentral
11.
go back to reference Marconi VC, Grandits G, Okulicz JF, Wortmann G, Ganesan A, Crum-Cianflone N, et al. Cummulative viral load and virologic decay patterns after antiretroviral therapy in HIV-infected subjects influence CD4 recovery and AIDS. PLoS One. 2011;6, e17956.CrossRefPubMedPubMedCentral Marconi VC, Grandits G, Okulicz JF, Wortmann G, Ganesan A, Crum-Cianflone N, et al. Cummulative viral load and virologic decay patterns after antiretroviral therapy in HIV-infected subjects influence CD4 recovery and AIDS. PLoS One. 2011;6, e17956.CrossRefPubMedPubMedCentral
12.
go back to reference Guest JL, Weintrob AC, Rimland D, Rentsch C, Bradley WP, Agan BK, et al. A comparison of HAART outcomes between the US military HIV natural history study (NHS) and HIV Atlanta veterans affairs cohort study (HAVACS). PLoS One. 2013;8, e62273.CrossRefPubMedPubMedCentral Guest JL, Weintrob AC, Rimland D, Rentsch C, Bradley WP, Agan BK, et al. A comparison of HAART outcomes between the US military HIV natural history study (NHS) and HIV Atlanta veterans affairs cohort study (HAVACS). PLoS One. 2013;8, e62273.CrossRefPubMedPubMedCentral
13.
go back to reference Molina JM, Cahn P, Grinstzejn B, Lazzarin A, Mills A, Saag M, et al. Rilpivirine versus egavirenz with tenofovir and emtricitabine in treatment-naïve adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011;378:238–46.CrossRefPubMed Molina JM, Cahn P, Grinstzejn B, Lazzarin A, Mills A, Saag M, et al. Rilpivirine versus egavirenz with tenofovir and emtricitabine in treatment-naïve adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011;378:238–46.CrossRefPubMed
14.
go back to reference Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.CrossRefPubMed Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.CrossRefPubMed
15.
go back to reference Chesney MA. The elusive gold standard. Future perspectives for HIV adherence assessment and intervention. J Acquir Immune Defic Syndr. 2006;43:S149–55.CrossRefPubMed Chesney MA. The elusive gold standard. Future perspectives for HIV adherence assessment and intervention. J Acquir Immune Defic Syndr. 2006;43:S149–55.CrossRefPubMed
16.
go back to reference Mannheimer SB, Morse E, Matts JP, Andrews L, Child C, Schmetter B, et al. Sustained benefit from a long-term antiretroviral adherence intervention. Results of a large randomized clinical trial. J Acquir Immune Defic Syndr. 2006;43:S41–7.CrossRefPubMed Mannheimer SB, Morse E, Matts JP, Andrews L, Child C, Schmetter B, et al. Sustained benefit from a long-term antiretroviral adherence intervention. Results of a large randomized clinical trial. J Acquir Immune Defic Syndr. 2006;43:S41–7.CrossRefPubMed
17.
go back to reference Rodger AJ, Lodwick R, Schechter M, Deeks S, Amin J, Gilson R, et al. Mortality in well controlled HIV in the continous antiretroviral therapy arms of SMART and ESPIRIT trials compared with the general population. AIDS. 2013;27:973–9.CrossRefPubMed Rodger AJ, Lodwick R, Schechter M, Deeks S, Amin J, Gilson R, et al. Mortality in well controlled HIV in the continous antiretroviral therapy arms of SMART and ESPIRIT trials compared with the general population. AIDS. 2013;27:973–9.CrossRefPubMed
18.
go back to reference The Antiretroviral Therapy (ART) Cohort Collaboration. HIV treatment response and prognosis in Europe and north America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet. 2006;368:451–8.CrossRef The Antiretroviral Therapy (ART) Cohort Collaboration. HIV treatment response and prognosis in Europe and north America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet. 2006;368:451–8.CrossRef
19.
go back to reference D’Arminio Monforte A, Testa L, Adorni F, Chiesa E, Bini T, Moscatelli GC, et al. Clinical outcome and predictors factors of failure of highly active antiretroviral therapy in antiretroviral experienced patients in advanced stages of HIV-1 infection. AIDS. 1998;12:1631–7.CrossRefPubMed D’Arminio Monforte A, Testa L, Adorni F, Chiesa E, Bini T, Moscatelli GC, et al. Clinical outcome and predictors factors of failure of highly active antiretroviral therapy in antiretroviral experienced patients in advanced stages of HIV-1 infection. AIDS. 1998;12:1631–7.CrossRefPubMed
20.
go back to reference Mocroft A, Youle M, Moore A, Sabin CA, Madge S, Lepri AC, et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS. 2001;15:185–94.CrossRefPubMed Mocroft A, Youle M, Moore A, Sabin CA, Madge S, Lepri AC, et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS. 2001;15:185–94.CrossRefPubMed
21.
go back to reference Van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, Young B, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis. 2012;12:111–8.CrossRefPubMed Van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, Young B, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis. 2012;12:111–8.CrossRefPubMed
22.
go back to reference Sax PE, Dejesus E, Mills A, Zolopa A, Cohen C, Wohl D, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012;379:2439–48.CrossRefPubMed Sax PE, Dejesus E, Mills A, Zolopa A, Cohen C, Wohl D, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012;379:2439–48.CrossRefPubMed
23.
go back to reference Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81–7.CrossRefPubMed Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81–7.CrossRefPubMed
24.
go back to reference Grabar S, Pradier C, Le Corfec E, Lancar R, Allavena C, Bentata M, et al. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS. 2000;14:141–9.CrossRefPubMed Grabar S, Pradier C, Le Corfec E, Lancar R, Allavena C, Bentata M, et al. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS. 2000;14:141–9.CrossRefPubMed
25.
go back to reference Kaufmann GR, Bloch M, Zaunders JJ, Smith D, Cooper DA. Long-term immunlogical response in HIV-1 infected subjects receiving potent antiretroviral therapy. AIDS. 2000;14:959–69.CrossRefPubMed Kaufmann GR, Bloch M, Zaunders JJ, Smith D, Cooper DA. Long-term immunlogical response in HIV-1 infected subjects receiving potent antiretroviral therapy. AIDS. 2000;14:959–69.CrossRefPubMed
26.
go back to reference Wood E, Yip B, Hogg RS, Sherlock CH, Jahnke N, Harrigan NP, et al. Full supression of viral loads is needed to achieve an optimal CD4 cell count among patients on triple drug antiretroviral therapy. AIDS. 2000;14:1955–60.CrossRefPubMed Wood E, Yip B, Hogg RS, Sherlock CH, Jahnke N, Harrigan NP, et al. Full supression of viral loads is needed to achieve an optimal CD4 cell count among patients on triple drug antiretroviral therapy. AIDS. 2000;14:1955–60.CrossRefPubMed
27.
go back to reference Althoff KN, Rebeiro P, Brooks JT, Buchacz K, Gebo K, Martin J, et al. Disparities in the quality of HIV care when using US Department of Health and Human Service Indicators. Clin Infect Dis. 2014; doi:10.1093/cid/ciu044. Althoff KN, Rebeiro P, Brooks JT, Buchacz K, Gebo K, Martin J, et al. Disparities in the quality of HIV care when using US Department of Health and Human Service Indicators. Clin Infect Dis. 2014; doi:10.​1093/​cid/​ciu044.
28.
go back to reference Willis S, Castel AD, Ahmed T, Olejemeh C, Frison L, Kharfen M. Linkage, engagement, and viral suppression rates among HIV-infected persons receiving care at medical care at medical case management in Washington, DC. JAIDS. 2013;64:S33–41.PubMed Willis S, Castel AD, Ahmed T, Olejemeh C, Frison L, Kharfen M. Linkage, engagement, and viral suppression rates among HIV-infected persons receiving care at medical care at medical case management in Washington, DC. JAIDS. 2013;64:S33–41.PubMed
29.
go back to reference Eberhart MG, Yehia BR, Hillier A, Voytek CD, Blank MB, Frank I, et al. Behind the cascade: analyzing spatial patterns along HIV care continuum. JAIDS. 2013;64:S42–51.PubMedPubMedCentral Eberhart MG, Yehia BR, Hillier A, Voytek CD, Blank MB, Frank I, et al. Behind the cascade: analyzing spatial patterns along HIV care continuum. JAIDS. 2013;64:S42–51.PubMedPubMedCentral
30.
go back to reference Weintrob AC, Grandits GA, Agan BK, Ganesan A, Landrum ML, Crum-Cianflone NF, et al. Virologic response differences between African Americans and European Americans initating highly active antiretroviral therapy with equal access to care. JAIDS. 2009;52:574–80.PubMed Weintrob AC, Grandits GA, Agan BK, Ganesan A, Landrum ML, Crum-Cianflone NF, et al. Virologic response differences between African Americans and European Americans initating highly active antiretroviral therapy with equal access to care. JAIDS. 2009;52:574–80.PubMed
31.
go back to reference Brodine SK, Starkey MJ, Shaffer RA, Ito SI, Tasker SA, Barile AJ, et al. Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort. AIDS. 2003;17:2521–7.CrossRefPubMed Brodine SK, Starkey MJ, Shaffer RA, Ito SI, Tasker SA, Barile AJ, et al. Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort. AIDS. 2003;17:2521–7.CrossRefPubMed
32.
go back to reference Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Behav. 2006;10:227–45.CrossRefPubMedPubMedCentral Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Behav. 2006;10:227–45.CrossRefPubMedPubMedCentral
33.
go back to reference Arnsten JH, Demas PA, Farzadegan H, Grant RW, Gourevitch MN, Chang CJ, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-rpeort and electronic monitoring. Clin Infect Dis. 2001;33:1417–23.CrossRefPubMedPubMedCentral Arnsten JH, Demas PA, Farzadegan H, Grant RW, Gourevitch MN, Chang CJ, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-rpeort and electronic monitoring. Clin Infect Dis. 2001;33:1417–23.CrossRefPubMedPubMedCentral
34.
go back to reference Martin S, Elliott-Desorbo DK, Calabrese S, Wolters PL, Roby G, Brennan T, et al. A comparison of adherence assessment methods utilized in the united states: perspectives of researchers, HIV-infected children, and their caregivers. AIDS Patient Care STDS. 2009;23:593–603.CrossRefPubMedPubMedCentral Martin S, Elliott-Desorbo DK, Calabrese S, Wolters PL, Roby G, Brennan T, et al. A comparison of adherence assessment methods utilized in the united states: perspectives of researchers, HIV-infected children, and their caregivers. AIDS Patient Care STDS. 2009;23:593–603.CrossRefPubMedPubMedCentral
Metadata
Title
Factors associated with 10 years of continuous viral load suppression on HAART
Authors
Kathryn J. Bello
Octavio Mesner
Thomas A. O’Bryan
Seung Hyun Won
Tahaniyat Lalani
Anuradha Ganesan
Brian K. Agan
Jason F. Okulicz
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2016
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-016-1677-x

Other articles of this Issue 1/2016

BMC Infectious Diseases 1/2016 Go to the issue